GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about General Updates
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has issued a Postal Ballot Notice seeking shareholder approval for the appointment of Mr. Ronojit Biswas as a Director and as Whole-time Director & Chief Financial Officer, effective 1st April 2026 for a 3-year term ending 31st March 2029. Mr. Biswas is a 25+ year GSK veteran who has held senior finance roles in India, Vietnam, Singapore, Brazil, and the UK, and currently serves as Senior Finance Director – Global Product Strategy in Singapore. His proposed pay package includes a basic salary of up to Rs. 16 lakh per month, a Rs. 20 lakh sign-on bonus (recoverable if he leaves within a year), a performance bonus of up to 100% of basic salary, long-term incentive/ESOP benefits under GSK group schemes, and perquisites capped at 2x annual salary. E-voting will run from 9 March 2026 (9:00 AM) to 8 April 2026 (5:00 PM), with the cut-off date for eligibility being 27 February 2026. Results are expected to be announced on or before 10 April 2026.
Routine governance action with no direct impact on operations or financials, though the induction of an internal GSK candidate as CFO signals continuity in finance leadership. Shareholders should note the e-voting window if they wish to participate; pay disclosures give visibility into senior executive compensation at the company.